MedPacto Voluntarily Withdraws Phase 2 Clinical Trial Related to Desmoid Tumors

"Due to Development Plan Changes Following Portfolio Adjustment"

[Asia Economy Reporter Chunhee Lee] MedPacto announced on the 23rd that it will withdraw the Phase 2 clinical trial related to desmoid tumors, for which it had received approval for the Investigational New Drug (IND) application and was preparing.

MedPacto disclosed on the same day that it is voluntarily withdrawing the Phase 2 clinical trial titled "Comparison of Vactosertib and Imatinib Combination Therapy versus Imatinib Monotherapy in Progressive Desmoid Tumors (Aggressive Fibromatosis) (MP-VAC-206)."

This clinical trial had been approved by the Ministry of Food and Drug Safety in November of last year. At that time, MedPacto explained, "There are currently no approved drugs for the treatment of desmoid tumors," and "Imatinib is considered one of the systemic therapies recommended according to the NCCN guidelines." They also stated that there was a possibility that the combination therapy of Vactosertib and Imatinib could demonstrate efficacy surpassing that of Imatinib monotherapy.

However, MedPacto announced that it will voluntarily withdraw this clinical trial. The company added that no patient recruitment or dosing has been conducted to date.

Regarding this, MedPacto explained that the withdrawal is due to changes in the development plan. Since desmoid tumors require long-term observation and the market size is not large, there are difficulties in accelerating the clinical trial progress. Therefore, the company revised its strategy to focus its capabilities on clinical trials of cancer types that can be commercialized earlier, adjusting its clinical portfolio accordingly.